Advertisement

Journal of Neuro-Oncology

, Volume 109, Issue 1, pp 63–70 | Cite as

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

  • Emil Lou
  • Ashley L. Sumrall
  • Scott Turner
  • Katherine B. Peters
  • Annick Desjardins
  • James J. Vredenburgh
  • Roger E. McLendon
  • James E. HerndonII
  • Frances McSherry
  • Julie Norfleet
  • Henry S. Friedman
  • David A. ReardonEmail author
Clinical Study

Abstract

Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and effective therapies have yet to be identified. Preclinical studies implicate angiogenesis in the pathophysiology of more aggressive meningiomas, suggesting that anti-angiogenic therapies may be of utility in this setting. We performed a retrospective review of fourteen patients with recurrent meningioma treated at Duke University Medical Center with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, administered either alone or in combination with chemotherapy. Most patients were heavily pre-treated. Progression-free survival at 6 months was 86 % and was comparable regardless of meningioma grade and whether bevacizumab was administered as monotherapy or in combination with chemotherapy. Most toxicities were mild however single patients developed CNS hemorrhage (grade 1) and intestinal perforation (grade 4), respectively. Bevacizumab can be administered safely to patients with meningioma and appears to be associated with encouraging anti-tumor effect when administered as either a single agent or in combination with chemotherapy. Phase II trials investigating bevacizumab in patients with progressive/recurrent meningioma are warranted.

Keywords

Meningioma Angiogenesis Vascular endothelial growth factor Bevacizumab 

Notes

Acknowledgments

This work was supported by NIH Grants 5P50-NS-20023 and 5 R37 CA11898; NIH Grant MO1 RR 30, GCRC Program, NCRR; and NCI SPORE 1 P20 CA096890; and a grant from Genentech Pharmaceuticals.

The authors thank Wendy Gentry for her excellent secretarial support in the development of this manuscript.

References

  1. 1.
    CBTRUS (2010) CBTRUS: 2010 statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2006Google Scholar
  2. 2.
    Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379–391. doi: 10.1007/s11060-010-0342-2 PubMedCrossRefGoogle Scholar
  3. 3.
    Alexiou GA, Gogou P, Markoula S, Kyritsis AP (2010) Management of meningiomas. Clin Neurol Neurosurg 112:177–182. doi: 10.1016/j.clineuro.2009.12.011 PubMedCrossRefGoogle Scholar
  4. 4.
    Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD (2010) Medical therapies for meningiomas. J Neurooncol 99:365–378. doi: 10.1007/s11060-010-0349-8 PubMedCrossRefGoogle Scholar
  5. 5.
    Hanft S, Canoll P, Bruce JN (2010) A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol 99:433–443. doi: 10.1007/s11060-010-0348-9 PubMedCrossRefGoogle Scholar
  6. 6.
    Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341–346. doi: 10.3171/jns.2002.97.2.0341 PubMedCrossRefGoogle Scholar
  7. 7.
    Newton HB (2007) Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus 23:E11PubMedCrossRefGoogle Scholar
  8. 8.
    Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18:495–499PubMedCrossRefGoogle Scholar
  9. 9.
    Rosenthal MA, Ashley DL, Cher L (2002) Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci 9:156–158. doi: 10.1054/jocn.2001.1019S0967586801910197 PubMedCrossRefGoogle Scholar
  10. 10.
    Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A (2004) Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67:221–226PubMedCrossRefGoogle Scholar
  11. 11.
    Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840–844PubMedCrossRefGoogle Scholar
  12. 12.
    Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-oncology 11:853–860. doi: 10.1215/15228517-2009-010 PubMedCrossRefGoogle Scholar
  13. 13.
    Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96:211–217. doi: 10.1007/s11060-009-9948-7 PubMedCrossRefGoogle Scholar
  14. 14.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedCrossRefGoogle Scholar
  15. 15.
    Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027PubMedCrossRefGoogle Scholar
  16. 16.
    Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M, Lupi G, Leocata P, Basolo F, Pingitore R, Parenti G, Fontanini G (2004) Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol 30:118–125PubMedCrossRefGoogle Scholar
  17. 17.
    Rogers L, Gilbert M, Vogelbaum MA (2010) Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol 99:393–405. doi: 10.1007/s11060-010-0343-1 PubMedCrossRefGoogle Scholar
  18. 18.
    Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131–1138Google Scholar
  19. 19.
    Barresi V, Tuccari G (2009) Evaluation of neo-angiogenesis in a case of chordoid meningioma. J Neurooncol 95:445–447PubMedCrossRefGoogle Scholar
  20. 20.
    Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A (1997) Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 40:1016–1026PubMedCrossRefGoogle Scholar
  21. 21.
    Maiuri F, De Caro MB, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, de Divitiis E (2007) Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 82:63–68PubMedCrossRefGoogle Scholar
  22. 22.
    Otsuka S, Tamiya T, Ono Y, Michiue H, Kurozumi K, Daido S, Kambara H, Date I, Ohmoto T (2004) The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neurooncol 70:349–357PubMedCrossRefGoogle Scholar
  23. 23.
    Yoshioka H, Hama S, Taniguchi E, Sugiyama K, Arita K, Kurisu K (1999) Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer 85:936–944PubMedCrossRefGoogle Scholar
  24. 24.
    Ragel BT, Jensen RL (2010) Aberrant signaling pathways in meningiomas. J Neurooncol 99:315–324. doi: 10.1007/s11060-010-0381-8 PubMedCrossRefGoogle Scholar
  25. 25.
    Goldman CK, Bharara S, Palmer CA, Vitek J, Tsai JC, Weiss HL, Gillespie GY (1997) Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 40:1269–1277PubMedCrossRefGoogle Scholar
  26. 26.
    Kalkanis SN, Carroll RS, Zhang J, Zamani AA, Black PM (1996) Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas. J Neurosurg 85:1095–1101. doi: 10.3171/jns.1996.85.6.1095 PubMedCrossRefGoogle Scholar
  27. 27.
    Ding YS, Wang HD, Tang K, Hu ZG, Jin W, Yan W (2008) Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci 38:344–351PubMedGoogle Scholar
  28. 28.
    Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740PubMedCrossRefGoogle Scholar
  29. 29.
    Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745PubMedCrossRefGoogle Scholar
  30. 30.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972PubMedCrossRefGoogle Scholar
  31. 31.
    Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U (2010) Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 21:2445–2446. doi: 10.1093/annonc/mdq634 PubMedCrossRefGoogle Scholar
  32. 32.
    DeBoer R, Grimm SA, Chandler J, Gallot L, Kennedy S, Burns K, Rice L, Cabreza C, Muro K, Raizer JJ (2008) A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas. J Clin Oncol [2008 ASCO annual meeting proceedings (post-meeting edition)] 26:2060Google Scholar
  33. 33.
    Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE II, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS (2011) Phase II study of Gleevec((R)) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J. J Neurooncol. doi: 10.1007/s11060-011-0687-1 Google Scholar
  34. 34.
    Chamberlain MC, Johnston SK (2011) Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol. doi: 10.1007/s11060-011-0541-5 Google Scholar
  35. 35.
    Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 78:271–276PubMedCrossRefGoogle Scholar
  36. 36.
    Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG (2005) Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol 74:157–165. doi: 10.1007/s11060-004-2337-3 PubMedCrossRefGoogle Scholar
  37. 37.
    Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62:1210–1212PubMedCrossRefGoogle Scholar
  38. 38.
    Chamberlain MC, Glantz MJ (2008) Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113:2146–2151PubMedCrossRefGoogle Scholar
  39. 39.
    Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC (2011) Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol 13:530–535. doi: 10.1093/neuonc/nor044 PubMedCrossRefGoogle Scholar
  40. 40.
    Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69:969–973PubMedCrossRefGoogle Scholar
  41. 41.
    Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 15:75–77PubMedCrossRefGoogle Scholar
  42. 42.
    Grunberg SM, Rankin C, Townsend J et al (2001) Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unreasectable meningioma. Proc Am Soc Clin Oncol 20:222Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Emil Lou
    • 1
    • 2
  • Ashley L. Sumrall
    • 1
  • Scott Turner
    • 1
  • Katherine B. Peters
    • 3
  • Annick Desjardins
    • 3
  • James J. Vredenburgh
    • 3
  • Roger E. McLendon
    • 4
  • James E. HerndonII
    • 5
  • Frances McSherry
    • 5
  • Julie Norfleet
    • 1
  • Henry S. Friedman
    • 1
    • 6
  • David A. Reardon
    • 1
    • 6
    • 7
    Email author
  1. 1.Department of Surgery, The Preston Robert Tisch Brain Tumor Center at DukeDuke University Medical CenterDurhamUSA
  2. 2.Department of Medicine, Division of Hematology, Oncology and TransplantationUniversity of MinnesotaMinneapolisUSA
  3. 3.Departments of Medicine, The Preston Robert Tisch Brain Tumor Center at DukeDuke University Medical CenterDurhamUSA
  4. 4.Department of Pathology, The Preston Robert Tisch Brain Tumor Center at DukeDuke University Medical CenterDurhamUSA
  5. 5.Cancer Center Biostatistics, The Preston Robert Tisch Brain Tumor CenterDuke University Medical CenterDurhamUSA
  6. 6.Department of Pediatrics, The Preston Robert Tisch Brain Tumor Center at DukeDuke University Medical CenterDurhamUSA
  7. 7.Center for Neuro-OncologyDana-Farber Cancer InstituteBostonUSA

Personalised recommendations